Form 4: Cingulate Inc. SVP and CFO Jennifer L. Callahan Reports Stock Option Grant
SEC Form 4 Filing
Jennifer L. Callahan, SVP and CFO of Cingulate Inc., reports the acquisition of stock options.
Summary
- On March 4, 2024, Jennifer L. Callahan, SVP and CFO of Cingulate Inc., acquired 25,014 stock options with an exercise price of $1.18.
- The options vest with 50% vesting on the six-month anniversary of the grant date, and the remaining shares vesting in substantially equal monthly installments over the following 30-month period.
- The options expire on March 4, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, and does not contain any information that would significantly impact investor sentiment positively or negatively.
Positives
- The grant of stock options to a key executive aligns their interests with those of the shareholders.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with the long-term success of the company.
Key Dates
| Date | Description |
|---|---|
| 03/04/2024 | Date of stock option grant |
| 03/04/2034 | Expiration date of the stock options |
Keywords
stock options, Form 4, Cingulate Inc., insider trading, Jennifer L. Callahan, SVP, CFO, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.